A Decade of Anti-Myeloma Vaccine Development through Early Phase Trials: A Systematic Review

ConclusionAnti-myeloma vaccination therapy appears to be well tolerated, which makes it a promising adjuvant therapeutic agent against MM. Current data reveals positive immunologic activity in most patients and there is possibility of promising clinical responses with further drug development.DisclosuresNo relevant conflicts of interest to declare.

Source: Blood - November 21, 2018 Category: Hematology Authors: Nunes Cavalcante Parr, N. C., Tariq, M. J., Usman, M., Fraz, M. A., Khan, A. Y., Samuel, S., Ijaz, A., Ahmad, M. Q., Khalil, M. J., Yasir, M., Amin, S. N., Safdar, A., Rafae, A., Anwer, F. Tags: 653. Myeloma: Therapy, excluding Transplantation Source Type: research